![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1b Infection: Phase 3 HALLMARK-DUAL Study Results
|
|
|
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng C-Y, Chang T-T, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu C-J, Sievert W, Bronowicki J-P, Thabut D, Lee Y-J, Kao J-H, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S, and the HALLMARK-DUAL Study Team
![EASL1.gif](../images/041414/041414-2/EASL1.gif)
![EASL2.gif](../images/041414/041414-2/EASL2.gif)
![EASL3.gif](../images/041414/041414-2/EASL3.gif)
![EASL4.gif](../images/041414/041414-2/EASL4.gif)
![EASL5.gif](../images/041414/041414-2/EASL5.gif)
![EASL6.gif](../images/041414/041414-2/EASL6.gif)
![EASL7.gif](../images/041414/041414-2/EASL7.gif)
![EASL8.gif](../images/041414/041414-2/EASL8.gif)
![EASL9.gif](../images/041414/041414-2/EASL9.gif)
![EASL10.gif](../images/041414/041414-2/EASL10.gif)
![EASL11.gif](../images/041414/041414-2/EASL11.gif)
![EASL12.gif](../images/041414/041414-2/EASL12.gif)
![EASL13.gif](../images/041414/041414-2/EASL13.gif)
![EASL14.gif](../images/041414/041414-2/EASL14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|